Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: The Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study

被引:15
|
作者
Engelberger, Rolf P. [1 ,2 ,3 ]
Noll, Georg [4 ]
Schmidt, Dominique
Alatri, Adriano [1 ]
Frei, Benedikt
Kaiser, Walter E. [5 ]
Kucher, Nils [2 ,3 ,6 ]
机构
[1] CHU Vaudois, Div Angiol, CH-1011 Lausanne, Switzerland
[2] Inselspital Bern, Univ Hosp, Swiss Cardiovasc Ctr, Clin Angiol, Bern, Switzerland
[3] Univ Bern, CH-3012 Bern, Switzerland
[4] Klin Hirslanden, HerzKlin, Zurich, Switzerland
[5] DocWorld AG, Menzingen, Switzerland
[6] Univ Hosp, Inselspital, Swiss Cardiovasc Ctr, Clin Cardiol, Bern, Switzerland
关键词
Atrial fibrillation; Primary care; Rivaroxaban; Stroke prevention; Treatment satisfaction; STROKE PREVENTION; ANTITHROMBOTIC THERAPY; TREATMENT SATISFACTION; ORAL ANTICOAGULATION; WARFARIN; RISK; DABIGATRAN; ADHERENCE; MANAGEMENT; PHYSICIANS;
D O I
10.1016/j.ejim.2015.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rivaroxaban has become an alternative to vitamin-K antagonists (VKA) for stroke prevention in non-valvular atrial fibrillation (AF) patients due to its favourable risk-benefit profile in the restrictive setting of a large randomized trial. However in the primary care setting, physician's motivation to begin with rivaroxaban, treatment satisfaction and the clinical event rate after the initiation of rivaroxaban are not known. Methods: Prospective data collection by 115 primary care physicians in Switzerland on consecutive nonvalvular AF patients with newly established rivaroxaban anticoagulation with 3-month follow-up. Results: We enrolled 537 patients (73 +/- 11 years, 57% men) with mean CHADS2 and HAS-BLED-scores of 2.2 +/- 1.3 and 2.4 +/- 1.1, respectively: 301(56%) were switched from VKA to rivaroxaban (STR-group) and 236(44%) were VKA-naive (VN-group). Absence of routine coagulation monitoring (68%) and fixed-dose once-daily treatment (58%) were the most frequent criteria for physicians to initiate rivaroxaban. In the STR-group, patient's satisfaction increased from 3.6 +/- 1.4 under VKA to 5.5 +/- 0.8 points (P < 0.001), and overall physician satisfaction from 3.9 +/- 1.3 to 5.4 +/- 0.9 points (P < 0.001) at 3months of rivaroxaban therapy (score from 1 to 6 with higher scores indicating greater satisfaction). In the VN-group, both patient's (5.4 +/- 0.9) and physician's satisfaction (5.5 +/- 0.7) at follow-up were comparable to the STR-group. During follow-up, 1(0.19%; 95% CI, 0.01-1.03%) ischemic stroke, 2(0.37%; 95% CI, 0.05-1.34%) major non-fatal bleeding and 11(2.05%; 95% CI, 1.03-3.64%) minor bleeding complications occurred. Rivaroxaban was stopped in 30(5.6%) patients, with side effects being the most frequent reason. Conclusion: Initiation of rivaroxaban for patients with nonvalvular AF by primary care physicians was associated with a low clinical event rate and with high overall patient's and physician's satisfaction. (C) 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:508 / 514
页数:7
相关论文
共 50 条
  • [1] Early initiation of rivaroxaban after reperfusion therapy for stroke patients with nonvalvular atrial fibrillation
    Koge, Junpei
    Yamagami, Hiroshi
    Toyoda, Kazunori
    Yasaka, Masahiro
    Hirano, Teruyuki
    Hamasaki, Toshimitsu
    Nagao, Takehiko
    Yoshimura, Shinichi
    Fujishige, Masahito
    Tempaku, Akira
    Uchiyama, Shinichiro
    Mori, Etsuro
    Koga, Masatoshi
    Minematsu, Kazuo
    PLOS ONE, 2022, 17 (04):
  • [2] Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
    Patel, Manesh R.
    Mahaffey, Kenneth W.
    Garg, Jyotsna
    Pan, Guohua
    Singer, Daniel E.
    Hacke, Werner
    Breithardt, Guenter
    Halperin, Jonathan L.
    Hankey, Graeme J.
    Piccini, Jonathan P.
    Becker, Richard C.
    Nessel, Christopher C.
    Paolini, John F.
    Berkowitz, Scott D.
    Fox, Keith A. A.
    Califf, Robert M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (10): : 883 - 891
  • [3] Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
    Pearson, Scott
    Troughton, Richard
    Richards, A. Mark
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24): : 2334 - 2335
  • [4] Concomitant Rivaroxaban and Dronedarone Administration in Patients With Nonvalvular Atrial Fibrillation
    Escobar, Carlos
    Arceluz, Martin
    Montes de Oca, Rosa
    Mori, Ricardo
    Luis Lopez-Sendon, Jose
    Luis Merino, Jose
    REVISTA ESPANOLA DE CARDIOLOGIA, 2017, 70 (02): : 121 - 122
  • [5] Outcomes of Apixaban Versus Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation
    Jehle, D.
    Paul, K.
    Sorensen, B.
    ANNALS OF EMERGENCY MEDICINE, 2024, 84 (04) : S9 - S9
  • [6] Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy?
    Silva, Vanessa M.
    Scanavacca, Mauricio
    Darrieux, Francisco
    Cavalheiro, Cyrillo
    Strunz, Celia C.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2019, 25
  • [7] ANALYSIS OF COAGULATION IN VALVULAR ATRIAL-FIBRILLATION AND NONVALVULAR ATRIAL-FIBRILLATION
    USUI, H
    IWADE, K
    AOSAKI, M
    OHKI, K
    MORI, F
    KAJIMOTO, K
    HOSODA, S
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 799 - 799
  • [8] Efficacy and safety of rivaroxaban in prevention and therapy of thromboembolic events in patients with nonvalvular atrial fibrillation
    Preradovic, Tamara
    Miljkovic, Sinisa
    Kos, Ljiljana
    Sukalo, Aziz
    Glamoclija, Una
    Avdic, Amna
    Mehic, Meliha
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2023, 9 (02) : 110 - 115
  • [9] Evaluating Rivaroxaban for Nonvalvular Atrial Fibrillation - Regulatory Considerations
    Fleming, Thomas R.
    Emerson, Scott S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (17): : 1557 - 1559
  • [10] Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation REPLY
    Patel, Manesh R.
    Fox, Keith A. A.
    Califf, Robert M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24): : 2335 - 2335